181 related articles for article (PubMed ID: 20733549)
1. The National Cancer Institute Experimental Therapeutics program.
Doroshow JH
Clin Adv Hematol Oncol; 2010 Jun; 8(6):403-4. PubMed ID: 20733549
[No Abstract] [Full Text] [Related]
2. Institutional profile: Developing and evaluating new drugs for cancer treatment: perspectives from the US National Cancer Institute.
Trimble EL; Abrams JS; Ansher SS; Smith MA; Zwiebel JA; Tomaszewski JE
Future Med Chem; 2010 Apr; 2(4):555-9. PubMed ID: 21426005
[No Abstract] [Full Text] [Related]
3. NCI Cancer Imaging Program update.
Croft BY
J Nucl Med; 2008 Jun; 49(6):40N-42N. PubMed ID: 18511822
[No Abstract] [Full Text] [Related]
4. Current NHLBI perspectives on translational heart failure research.
Lathrop DA; Skarlatos S
J Mol Cell Cardiol; 2011 Oct; 51(4):441-3. PubMed ID: 20946899
[No Abstract] [Full Text] [Related]
5. The preclinical new drug research program of the National Cancer Institute.
Driscoll JS
Cancer Treat Rep; 1984 Jan; 68(1):63-76. PubMed ID: 6692438
[TBL] [Abstract][Full Text] [Related]
6. Clinical development of anticancer agents--a National Cancer Institute perspective.
Marsoni S; Wittes R
Cancer Treat Rep; 1984 Jan; 68(1):77-85. PubMed ID: 6362870
[No Abstract] [Full Text] [Related]
7. Report of the Cancer Chemotherapy Collaborative Program Review Committee: the Richardson report. June 1966, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Cancer Treat Rep; 1984 Jan; 68(1):343-56. PubMed ID: 6692435
[No Abstract] [Full Text] [Related]
8. NIH and NCI support for development of novel therapeutics in gynecologic cancer: a user's guide.
Minig L; Trimble EL; Birrer MJ; Kim KY; Takebe N; Abrams JS
Gynecol Oncol; 2010 Feb; 116(2):177-80. PubMed ID: 19889449
[TBL] [Abstract][Full Text] [Related]
9. Newsmaker interview: Harold Varmus. Piloting cancer research with a shrinking budget. Interview by Jocelyn Kaiser.
Varmus H
Science; 2011 Jul; 333(6041):397. PubMed ID: 21778374
[No Abstract] [Full Text] [Related]
10. Investigational trials of anticancer drugs: establishing safeguards for experimentation.
Chabner BA; Wittes R; Hoth D; Hubbard S
Public Health Rep; 1984; 99(4):355-60. PubMed ID: 6431482
[TBL] [Abstract][Full Text] [Related]
11. Research spotlight: The Cooperative Research Centre for Cancer Therapeutics: bridging the gap between leading cancer research at Australia's universities and developing novel cancer drugs.
Baell JB; Heathers G; Sage C
Future Med Chem; 2010 Jun; 2(6):941-7. PubMed ID: 21426113
[No Abstract] [Full Text] [Related]
12. From the editor. Translational Research Working Group roadmaps for cancer research.
Bates SE
Clin Cancer Res; 2008 Sep; 14(18):5663. PubMed ID: 18794073
[No Abstract] [Full Text] [Related]
13. Academia-industry alliance: Belfer Institute and sanofi-aventis collaborate to develop new cancer therapeutics.
Dis Model Mech; 2010; 3(11-12):669. PubMed ID: 21030419
[No Abstract] [Full Text] [Related]
14. Current investigational drugs of interest in the Chemotherapy Program of the National Cancer Institute.
Carter SK; Slavik M
Natl Cancer Inst Monogr; 1977 Mar; (45):101-21. PubMed ID: 73134
[No Abstract] [Full Text] [Related]
15. Update on the National Cancer Institute's clinical trials cooperative group program.
Wallner PE
J Am Coll Radiol; 2004 Nov; 1(11):865-6. PubMed ID: 17411719
[No Abstract] [Full Text] [Related]
16. Origins and development of chemotherapy research at the National Cancer Institute.
Zubrod CG
Cancer Treat Rep; 1984 Jan; 68(1):9-19. PubMed ID: 6362871
[No Abstract] [Full Text] [Related]
17. NCI seeks to speed drug development for pediatric cancers: New initiative aims to help prioritize agents with most potential.
Printz C
Cancer; 2016 Feb; 122(4):499-500. PubMed ID: 26844936
[No Abstract] [Full Text] [Related]
18. Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute.
Christian MC; Pluda JM; Ho PT; Arbuck SG; Murgo AJ; Sausville EA
Semin Oncol; 1997 Apr; 24(2):219-40. PubMed ID: 9129691
[TBL] [Abstract][Full Text] [Related]
19. Community networks program hits 5-year mark.
Printz C
Cancer; 2010 Apr; 116(8):1841-3. PubMed ID: 20391427
[No Abstract] [Full Text] [Related]
20. The role of the National Cancer Institute in drug development.
Doroshow J
Clin Adv Hematol Oncol; 2005 Apr; 3(4):257-8. PubMed ID: 16166997
[No Abstract] [Full Text] [Related]
[Next] [New Search]
